QUIDELORTHO CORPORATION QuidelOrtho Corporation Share Price
Equities
QDEL
US2197981051
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.64 USD | -0.13% |
|
+1.33% | -46.21% |
| 02/04 | QuidelOrtho Shares Fall on Decision to Withdraw FDA 510(k) Submission for Savanna RVP4+ Assay | MT |
| 02/04 | QuidelOrtho Gets US FDA Clearance For QuickVue COVID-19 Test | MT |
| Sales 2024 * | 2.79B 233B | Sales 2025 * | 2.91B 242B | Capitalization | 2.65B 221B |
|---|---|---|---|---|---|
| Net income 2024 * | -65M -5.42B | Net income 2025 * | 85M 7.09B | EV / Sales 2024 * | 1.69 x |
| Net Debt 2024 * | 2.06B 172B | Net Debt 2025 * | 1.74B 145B | EV / Sales 2025 * | 1.51 x |
| P/E ratio 2024 * |
-40.7
x | P/E ratio 2025 * |
31.3
x | Employees | 7,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 79.96% |
More Fundamentals
* Assessed data
More news
Latest transcript on QuidelOrtho Corporation
More recommendations
More press releases
| 1 day | -0.13% | ||
| 1 week | +1.33% | ||
| Current month | -17.31% | ||
| 1 month | -15.66% | ||
| 3 months | -43.66% | ||
| 6 months | -36.41% | ||
| Current year | -46.21% |
1 week
38.33
40.84
1 month
37.7849.08
Current year
37.7875.82
1 year
37.7895.02
3 years
37.78180.06
5 years
37.78306.72
10 years
13.21306.72
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Iskra
CEO | Chief Executive Officer | 54 | 01/22/01 |
Robert Bujarski
PSD | President | 55 | 01/05/01 |
Joseph Busky
DFI | Director of Finance/CFO | 56 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kenneth Widder
BRD | Director/Board Member | 71 | 01/14/01 |
Kenneth Buechler
CHM | Chairman | 70 | - |
Mary Polan
BRD | Director/Board Member | 80 | 01/93/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.24% | 215 M€ | +10.68% | - | |
| 1.92% | 2 M€ | +6.77% | ||
| 1.62% | 8 M€ | +2.44% | ||
| 0.98% | 16 M€ | -8.49% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 39.64 | -0.13% | 546,985 |
| 25/24/25 | 39.69 | -2.77% | 913,664 |
| 24/24/24 | 40.82 | +1.04% | 950,453 |
| 23/24/23 | 40.4 | +3.38% | 1,192,796 |
| 22/24/22 | 39.08 | -0.10% | 907,832 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotes
QuidelOrtho Corporation is engaged in vitro diagnostics, developing and manufacturing intelligent solutions. The Company sells its products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other point-of-care (POC) settings, blood banks and donor centers, as well as for individual, non-professional, over the counter (OTC) use. The Company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Connect, Ortho Plus, Ortho Vision, QuickVue, Quidel, QuidelOrtho, QVue, Savanna, Sofia, Solana, Thyretain, Triage, Virena, Vitros among others. It provides support for its customers across more than 130 countries and territories.
Calendar
08/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
39.64
USD
Average target price
54.73
USD
Spread / Average Target
+38.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -46.21% | 2.65B | |
| -12.91% | 19.08B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -18.10% | 682M | |
| -7.14% | 716M | |
| -.--% | 301M |
- Stock Market
- Equities
- QDEL Stock
